COVID-19

AbnomX is proud to partner with industry leaders to respond to this global health pandemic

At AbnomX, we are unlocking the potential of the immune repertoire to detect and treat disease to develop clinical products. Understanding the immune response to COVID-19 may lead to solutions to accelerate progress in the fight against the disease.

In April 2020, we welcomed the Faculdade Farmacia of the University of Lisbon to our list of users. They are using the latest version of Antibody-Extractor to investigate the antibody repertoire of COVID-19 patients.

In May 2020, Cold Spring Harbor Laboratories (New York, US) started using Antibody-Extractor to accelerate their COVID-19 research.

Biopharma partners

AbnomX is open to collaboration with academic institutions and private companies on antibody and TCR sequence analysis. Our commercial software solutions are complemented with a series of private, proprietary algorithms which the company uses for its own research efforts.

We collaborate to understand the mechanism of action and dosing, to identify immune fingerprint patterns of efficacy or adverse events. AbnomX invites parties interested in a collaboration to get in touch via bd@abnomx.com.

Strategic collaborations

AbnomX works with academic investigators, governmental scientific institutions, and research organizations globally to incorporate immune repertoire data analysis in their research and clinical trials across different disease settings.